New Drug Combination Shows Promise in Reducing Suicide Risk
A study presented at the American Psychiatric Association's annual meeting reveals that a combination of ketamine and low-dose buprenorphine significantly reduces suicidal ideation in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial involved 50 patients and showed sustained reductions in suicidal thoughts. The study authors highlight the potential of this drug regimen to provide rapid relief for individuals at risk of suicide, offering a new therapeutic option for a critical public health issue. 
